Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa KirinGlobeNewsWire • 11/03/25
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual MeetingGlobeNewsWire • 11/03/25
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa KirinGlobeNewsWire • 10/24/25
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology TranscriptSeeking Alpha • 10/18/25
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) CongressGlobeNewsWire • 10/18/25
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)GlobeNewsWire • 10/01/25
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)GlobeNewsWire • 09/29/25
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical OncologyGlobeNewsWire • 09/25/25
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor TypesGlobeNewsWire • 09/16/25
Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor ProgramGlobeNewsWire • 09/03/25
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes WellSeeking Alpha • 07/02/25